|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease:A controversial issue显示文摘Autophagy is a mechanism involved in cellular homeostasis under basal and stressed conditions delivering cytoplasmic content to the lysosomes for degradation to macronutrients.The potential role of autophagy in disease is increasingly recognised and investigated in the last decade.Nowadays it is commonly accepted that autophagy plays a role in the hepatic lipid metabolism.Hence,dysfunction of autophagy may be an underlying cause of non-alcoholic fatty liver disease.However,controversy of the exact role of autophagy in the lipid metabolism exists:some publications report a lipolytic function of autophagy,whereas others claim a lipogenic function.This review aims to give an update of the present knowledge on autophagy in the hepatic lipid metabolism,hepatic insulin resistance,steatohepatitis and hepatic fibrogenesis. | Wilhelmus J Kwanten Wim Martinet Peter P Michielsen Sven M Francque | 2014 | World Journal of Gastroenterology2014，20，23： | 17 |
| 2 | Synthetic peptide viccines : unexpected fullfillment of discarded Hope 显示文摘 | Rob H M Langeveld P M Wim M M | 2001 | Biologicals2001，29，34： | 1 |
| 3 | Genetic organization and heterogeneity of the iceA locus of Helicobacter pylori显示文摘 | Céu Figueiredo Wim G.V Quint Ricardo Sanna Erwin Sablon John P Donahue Qing Xu Geraldine G Miller Richard M Peek Martin J Blaser Leen-Jan van Doorn | 2000 | Gene2000，，1： | 1 |
| 4 | Synthetic peptide viccines : unexpected fullfillment of discarded hope 显示文摘 | Rob H M Langeveld P M Wim M M | 2001 | Biologicals2001，29，34： | 1 |
| 5 | Kinetic study of COS with tertiary Alkanolamine Solution显示文摘 | Rob J L Geet F V Wim P M | 1992 | Ind Eng Chem Res1992，31，5： | 1 |
| 6 | A novel interconnected fluidized bed for the combined flash pyrolysis of biomass and combustion of char显示文摘 | Arthur M C Janse P Maarten Biesheuvel Wolter Prins Wim P M van Swaaij | 2000 | Chemical Engineering Journal2000，，76： | 1 |
| 7 | Catalytic and noncatalytic gasification of pyrolysis oil 显示文摘 | Guus van Rossum Guus Kersten S R A Wim P M | 2007 | Industrial & Engineering Chemistry Research2007，46，12： | 1 |
| 8 | Profiling teachers'continuing professional development and the relation with their beliefs about learning and teaching 显示文摘 | Siebrich de Vries Jansen E P WA Wim J C M van de Grift | 2013 | Teaching and Teacher Education2013，33，7： | 1 |
| 9 | Polymerization of liquid propylene with a 4th generation Ziegler-Natta catalyst-influence of temperature,hydrogen and monomer concentration and prepolymerization method on polymerization kinetics显示文摘 | Jochem T M Pater Gunter Weickert Wim P M van Swaaij | | 0，，： | 1 |
| 10 | Polymerization of Liquid Propylene with a Fourth-Generation Ziegler-Natta Catalyst:Influence of Temperature,Hydrogen,Monomer Concentration,and Prepolymerization Method on Powder Morphology显示文摘 | Jochem T M Pater Gunter Weickert Wim P M van Swaaij | | 0，，： | 1 |
| 11 | Propene Bulk Polymerization Kinetics:Role of Prepolymerization and Hydrogen显示文摘 | Jochem T M Pater Gunter Weickert Wim P M van Swaaij | | 0，，01： | 1 |
| 12 | High Precision Prepolymerization of Propylene at Extremely Low Reaction Rates-Kinetics and Morphology显示文摘 | Jochem T M Pater Gunter Weickert Wim P M van Swaaij | | 0，，13： | 1 |
| 13 | Synthetic peptide viccines:unexpected fullfillment of discarded Hope显示文摘 | Rob H M Langeveld P M Wim M M | 2001 | Biologicals2001，29，34： | 1 |
| 14 | An explanation for the combined effect of xylanase-glucose oxidase in dough systems显示文摘 | Cristina P M Wang M W Wim J L | 2005 | Journal of the Science of Food and Agriculture2005，85，7： | 1 |
| 15 | Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial显示文摘 | Diane M Harper Eduardo L Franco Cosette Wheeler Daron G Ferris David Jenkins Anne Schuind Toufik Zahaf Bruce Innis Paulo Naud Newton S De Carvalho Cecilia M Roteli-Martins Julio Teixeira Mark M Blatter Abner P Korn Wim Quint Gary Dubin | 2004 | The Lancet2004，，9447： | 1 |
| 16 | Requirement for class II phosphoinositide 3-kinase C2 alpha in maintenance of glomerular structure and function显示文摘 | Harris DP Vopel P Wims M | 2011 | Mol Cell Biol2011，31，1： | 1 |
| 17 | Kinetic study of COS with tertiary alkanolamine solution显示文摘 | ROB J L GEET F V WIM P M | 1992 | Ind Eng Chem Res1992，31，5： | 1 |
| 18 | Access to biologicals in Crohn's disease in ten European countries显示文摘AIM To analyze access(availability, affordability and acceptability) to biologicals for Crohn's disease(CD) in ten European countries and to explore the associations between these dimensions, the uptake of biologicals and economic development.METHODS A questionnaire-based survey combined with desk research was carried out in May 2016. Gastroenterologists from the Czech Republic, France, Germany, Hungary, Latvia, Poland, Romania, Slovakia, Spain and Sweden were invited to participate and provide data on the availability of biologicals/biosimilars, reimbursement criteria, clinical practice and prices, and use of biologicals. An availability score was developed to evaluate the restrictiveness of eligibility and administrative criteria applied in the countries. Affordability was defined as the annual cost of treatment as a share of gross domestic product(GDP) per capita. Correlations with the uptake of biologicals, dimensions of access and GDP per capita were calculated.RESULTS At the time of the survey, infliximab and adalimumab were reimbursed in all ten countries, and vedolizumab was reimbursed in five countries(France, Germany, Latvia, Slovakia, Sweden). Reimbursement criteria were the least strict in Sweden and Germany, and the strictest in Hungary, Poland and Slovakia. Between countries, the annual cost of different biological treatments differed 1.6-3.3-fold. Treatments were the most affordable in Sweden(13%-37% of the GDP per capita) and the least affordable in the Central and Eastern European countries, especially in Hungary(87%-124%) and Romania(141%-277%). Biosimilars made treatments more affordable by driving down the annual costs. The number of patients with CD on biologicals per 100000 population was strongly correlated with GDP per capita(0.91), although substantial differences were found in the uptake among countries with similar economic development. Correlation between the number of patients with CD on biologicals per 100000 population and the availability and affordability was also strong(-0.75,-0.69 respectively). CONCLUSION Substantial inequalities in access to biologicals were largely associated with GDP. To explain differences in access among countries with similar development needs further research on acceptance. | Márta Péntek Peter L Lakatos Talitha Oorsprong László Gulácsi Milena Pavlova Wim Groot Fanni Rencz Valentin Brodszky Petra Baji Crohn’s Disease Research Group | 2017 | World Journal of Gastroenterology2017，23，34： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员